[Miser]

7
Comment
Favorite

CINDYTAN
2023-01-18

[Miser]

Moderna Says RSV Vaccine 84% Effective at Preventing Symptoms in Older Adults

Moderna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial vi

Moderna Says RSV Vaccine 84% Effective at Preventing Symptoms in Older Adults

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9956658321,"tweetId":"9956658321","gmtCreate":1673998729564,"gmtModify":1676538913704,"author":{"id":3581637081460043,"authorId":3581637081460043,"authorIdStr":"3581637081460043","name":"CINDYTAN","avatar":"https://static.tigerbbs.com/bbbe423bf9070ce2335568f8237e55b3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p><span>[Miser]&nbsp;</span></p></body></html>","htmlText":"<html><head></head><body><p><span>[Miser]&nbsp;</span></p></body></html>","text":"[Miser]","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9956658321","repostId":2304797527,"repostType":4,"repost":{"id":"2304797527","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1673997780,"share":"https://www.laohu8.com/m/news/2304797527?lang=&edition=full","pubTime":"2023-01-18 07:23","market":"us","language":"en","title":"Moderna Says RSV Vaccine 84% Effective at Preventing Symptoms in Older Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2304797527","media":"Reuters","summary":"Moderna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial vi","content":"<html><head></head><body><p>Moderna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.</p><p>RSV, which produces symptoms similar to a cold but can be fatal for young children and older adults, causes about 14,000 deaths annually in adults aged 65 and older. The disease surged in the United States and Europe this fall alongside the flu and COVID-19.</p><p>There is currently no vaccine for the virus in adults.  Moderna, Pfizer Inc and GSK Plc are racing to get their RSV vaccines to market first.</p><p>Pfizer and GSK filed applications for U.S. regulatory approval late last year. Pfizer&#39;s RSV vaccine was found to be 66.7% effective against two or more symptoms in late-stage trials.</p><p>On the other hand, <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> and partner <a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a>&#39;s antibody treatment nirsevimab has gained the European Commission&#39;s marketing authorization for the prevention of RSV in newborns and infants. It is currently under review by the U.S. Food and Drug Administration.</p><p>Moderna said it intends to submit its vaccine, mRNA-1345, for regulatory approval consideration globally in the first half of 2023.</p><p>The company&#39;s president, Stephen Hoge, told Reuters that its vaccine appears to compare favorably to the experimental Pfizer and GSK shots.</p><p>&#34;It&#39;s very exciting to see progress in RSV vaccines in older adults, and I think both of those vaccines have shown pretty remarkable results as well,&#34; Hoge said. &#34;We really think we&#39;re in that top class - 84% is a terrific efficacy number.&#34;</p><p>The RSV vaccine market could be worth more than $10 billion globally, half of which would come from the United States, according to Cowen analyst Tyler Van Buren.</p><p>Moderna&#39;s study was conducted in about 37,000 participants aged 60 years and older. The data analysis was performed after 64 participants contracted RSV. The company plans to release the full data at a medical meeting.</p><p>Hoge said Moderna had started secondary analyses on the vaccine&#39;s efficacy against more severe disease and hospitalization. He said it was too early to provide a potential price range for the vaccine it expects to be given annually.</p><p>The vaccine was generally found to be safe, with the most common side effects including injection-site pain, fatigue and headache. Hoge said there were no concerns of myocarditis, a type of heart inflammation linked to mRNA COVID vaccines.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Says RSV Vaccine 84% Effective at Preventing Symptoms in Older Adults</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Says RSV Vaccine 84% Effective at Preventing Symptoms in Older Adults\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2023-01-18 07:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Moderna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.</p><p>RSV, which produces symptoms similar to a cold but can be fatal for young children and older adults, causes about 14,000 deaths annually in adults aged 65 and older. The disease surged in the United States and Europe this fall alongside the flu and COVID-19.</p><p>There is currently no vaccine for the virus in adults.  Moderna, Pfizer Inc and GSK Plc are racing to get their RSV vaccines to market first.</p><p>Pfizer and GSK filed applications for U.S. regulatory approval late last year. Pfizer&#39;s RSV vaccine was found to be 66.7% effective against two or more symptoms in late-stage trials.</p><p>On the other hand, <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> and partner <a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a>&#39;s antibody treatment nirsevimab has gained the European Commission&#39;s marketing authorization for the prevention of RSV in newborns and infants. It is currently under review by the U.S. Food and Drug Administration.</p><p>Moderna said it intends to submit its vaccine, mRNA-1345, for regulatory approval consideration globally in the first half of 2023.</p><p>The company&#39;s president, Stephen Hoge, told Reuters that its vaccine appears to compare favorably to the experimental Pfizer and GSK shots.</p><p>&#34;It&#39;s very exciting to see progress in RSV vaccines in older adults, and I think both of those vaccines have shown pretty remarkable results as well,&#34; Hoge said. &#34;We really think we&#39;re in that top class - 84% is a terrific efficacy number.&#34;</p><p>The RSV vaccine market could be worth more than $10 billion globally, half of which would come from the United States, according to Cowen analyst Tyler Van Buren.</p><p>Moderna&#39;s study was conducted in about 37,000 participants aged 60 years and older. The data analysis was performed after 64 participants contracted RSV. The company plans to release the full data at a medical meeting.</p><p>Hoge said Moderna had started secondary analyses on the vaccine&#39;s efficacy against more severe disease and hospitalization. He said it was too early to provide a potential price range for the vaccine it expects to be given annually.</p><p>The vaccine was generally found to be safe, with the most common side effects including injection-site pain, fatigue and headache. Hoge said there were no concerns of myocarditis, a type of heart inflammation linked to mRNA COVID vaccines.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2304797527","content_text":"Moderna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.RSV, which produces symptoms similar to a cold but can be fatal for young children and older adults, causes about 14,000 deaths annually in adults aged 65 and older. The disease surged in the United States and Europe this fall alongside the flu and COVID-19.There is currently no vaccine for the virus in adults.  Moderna, Pfizer Inc and GSK Plc are racing to get their RSV vaccines to market first.Pfizer and GSK filed applications for U.S. regulatory approval late last year. Pfizer's RSV vaccine was found to be 66.7% effective against two or more symptoms in late-stage trials.On the other hand, Sanofi and partner AstraZeneca Plc's antibody treatment nirsevimab has gained the European Commission's marketing authorization for the prevention of RSV in newborns and infants. It is currently under review by the U.S. Food and Drug Administration.Moderna said it intends to submit its vaccine, mRNA-1345, for regulatory approval consideration globally in the first half of 2023.The company's president, Stephen Hoge, told Reuters that its vaccine appears to compare favorably to the experimental Pfizer and GSK shots.\"It's very exciting to see progress in RSV vaccines in older adults, and I think both of those vaccines have shown pretty remarkable results as well,\" Hoge said. \"We really think we're in that top class - 84% is a terrific efficacy number.\"The RSV vaccine market could be worth more than $10 billion globally, half of which would come from the United States, according to Cowen analyst Tyler Van Buren.Moderna's study was conducted in about 37,000 participants aged 60 years and older. The data analysis was performed after 64 participants contracted RSV. The company plans to release the full data at a medical meeting.Hoge said Moderna had started secondary analyses on the vaccine's efficacy against more severe disease and hospitalization. He said it was too early to provide a potential price range for the vaccine it expects to be given annually.The vaccine was generally found to be safe, with the most common side effects including injection-site pain, fatigue and headache. Hoge said there were no concerns of myocarditis, a type of heart inflammation linked to mRNA COVID vaccines.","news_type":1},"isVote":1,"tweetType":1,"viewCount":146,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}